ArticleHaematologica2022

A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials.

Min Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.